TrialJAMA dermatology2023

Long-term Outcomes After Rituximab Treatment for Patients With Systemic Sclerosis: Follow-up of the DESIRES Trial With a Focus on Serum Immunoglobulin Levels.

Ai Kuzumi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.